{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:17:58Z","timestamp":1789708678321,"version":"4.0.1"},"reference-count":29,"publisher":"National Institute for Health and Care Research","issue":"28","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["98\/04\/501"],"award-info":[{"award-number":["98\/04\/501"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The National Screening Committee (NSC) based its recommendation that human papillomavirus (HPV) testing should replace cytology in primary cervical screening largely on the 2009 follow-up results of the ARTISTIC trial (A Randomised Trial In Screening To Improve Cytology). The NSC must now decide on screening intervals and triage policy. Options include extending the screening interval up to 10 years for human papillomavirus-negative (HPV\u2013) women, delaying recall for human papillomavirus-positive (HPV+) women with normal cytology (as their infections are usually transient), and basing triage on full HPV typing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-2\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In ARTISTIC, 24,510 women were recruited who were attending routine cervical cytology in Greater Manchester in 2001\u20133. The women were randomly allocated between revealing and concealing their HPV test results and were recalled every 3 years. After 2009, the women returned to routine cytological screening with recall every 3 years for those aged &lt;\u200950 years, and every 5 years for those aged 50\u201364 years. We have followed the cohort to 2015 through national cancer registration for CIN3 (cervical intraepithelial neoplasia grade 3) and cancer, and through linkage to the cervical screening call\u2013recall system to obtain lifetime cytology records.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-3\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The analysis comprised 24,496 women at round 1 and 13,591 women at round 2 (which was 30\u201348 months later). Follow-up via local histology laboratories and national cancer registration identified 505 cases of cervical intraepithelial neoplasia grade 3 or cervical cancer (CIN3+) (including 22 invasive cervical cancers). The cumulative CIN3+ risk 10 years after a negative HPV test [0.31%, 95% confidence interval (CI) 0.18% to 0.49%, in the revealed arm] was similar to that 3 years after negative cytology (0.30%, 95% CI 0.23% to 0.41%, in the concealed arm) and fell sharply with age, from 1.1% (95% CI 0.7% to 1.8%) in those women aged &lt;\u200925 years to 0.08% (95% CI 0.03% to 0.20%) in those women aged &gt;\u200950 years. The 10-year cumulative CIN3+ risk following a new HPV infection at round 2 was 3.4% (95% CI 2.1% to 5.4%). The highest risks were associated with type-specific persistent infections that, overall, resulted in a 10-year cumulative CIN3+ risk of 20.4% (95% CI 15.6% to 26.4%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-4\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found a similar level of protection 10 years after a negative HPV test and 3 years after negative cytology. These data support a considerably longer screening interval after a negative HPV test than after a negative cytology test. About three-quarters of women with HPV infection and normal cytology clear their infections within about 3 years. Their risk of CIN3+ within this time frame is low (1.5%), suggesting that the current policy of annual repeat testing and referral after 2 years may be unnecessarily cautious. Approximately 40% of women who remained HPV+ had cleared their initial infection and acquired a new HPV type. The cumulative CIN3+ risks in women with type-specific persistent infections are about six times higher than in women with new infections. Triage strategies based on HPV persistence would, therefore, reduce unnecessary referral of women with new (and largely transient) infections. HPV assays that identify HPV types 31, 33, 45, 52 and 58 in addition to 16 and 18 could be useful in triage as well as in primary HPV testing. Similar results in recent routine HPV screening suggest that our results are generalisable despite changes in cytology and HPV assay methods. We are continuing to follow the ARTISTIC cohort into the new era of primary HPV screening. Future work will focus on the implications of more sensitive HPV testing for primary HPV screening policy and triage of HPV-positive women. Our results suggest that a more sensitive test is needed to detect occult CIN3 at high risk of progression to cancer, but this would substantially increase the overall HPV detection rate. Tests such as DNA (deoxyribonucleic acid) methylation for distinguishing HPV infection from neoplasia will be evaluated on stored samples and on further samples now being collected from women in the cohort who are still being screened.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"abs1-5\">\n                  <jats:title>Funding<\/jats:title>\n                  <jats:p>This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in <jats:italic>Health Technology Assessment<\/jats:italic>; Vol. 23, No. 28. See the NIHR Journals Library website for further project information.<\/jats:p>\n               <\/jats:sec>","DOI":"10.3310\/hta23280","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T10:32:33Z","timestamp":1561026753000},"page":"1-44","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":84,"title":["HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT"],"prefix":"10.3310","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9477-6090","authenticated-orcid":true,"given":"Clare","family":"Gilham","sequence":"first","affiliation":[{"name":"Non-Communicable Disease Epidemiology Unit, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9354-7720","authenticated-orcid":true,"given":"Alexandra","family":"Sargent","sequence":"additional","affiliation":[{"name":"Department of Virology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5791-7838","authenticated-orcid":true,"given":"Henry C","family":"Kitchener","sequence":"additional","affiliation":[{"name":"School of Cancer and Sciences, University of Manchester, St Mary\u2019s Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1685-8912","authenticated-orcid":true,"given":"Julian","family":"Peto","sequence":"additional","affiliation":[{"name":"Non-Communicable Disease Epidemiology Unit, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2019,6]]},"reference":[{"key":"key20190619124950825_ref1-bib1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(04)16674-9","article-title":"The cervical cancer epidemic that screening has prevented in the UK","volume":"364","author":"Peto","year":"2004","journal-title":"Lancet"},{"key":"key20190619124950825_ref1-bib2","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/bjc.2016.290","article-title":"Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study","volume":"115","author":"Landy","year":"2016","journal-title":"Br J Cancer"},{"issue":"51","key":"key20190619124950825_ref1-bib3","doi-asserted-by":"publisher","DOI":"10.3310\/hta13510","article-title":"ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening","volume":"13","author":"Kitchener","year":"2009","journal-title":"Health Technol Assess"},{"key":"key20190619124950825_ref1-bib4","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.ejca.2011.01.008","article-title":"A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial","volume":"47","author":"Kitchener","year":"2011","journal-title":"Eur J Cancer"},{"issue":"23","key":"key20190619124950825_ref1-bib5","doi-asserted-by":"publisher","DOI":"10.3310\/hta18230","article-title":"The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds","volume":"18","author":"Kitchener","year":"2014","journal-title":"Health Technol Assess"},{"key":"key20190619124950825_ref1-bib6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"key20190619124950825_ref1-bib7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/cyt.12236","article-title":"HPV primary cervical screening: time for a change","volume":"26","author":"Kitchener","year":"2015","journal-title":"Cytopathology"},{"key":"key20190619124950825_ref1-bib8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/sj.bjc.6603210","article-title":"HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial","volume":"95","author":"Kitchener","year":"2006","journal-title":"Br J Cancer"},{"key":"key20190619124950825_ref1-bib9","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1038\/sj.bjc.6604324","article-title":"Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial","volume":"98","author":"Sargent","year":"2008","journal-title":"Br J Cancer"},{"key":"key20190619124950825_ref1-bib10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(09)70156-1","article-title":"HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial","volume":"10","author":"Kitchener","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20190619124950825_ref1-bib11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1128\/JCM.00896-09","article-title":"Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial","volume":"48","author":"Sargent","year":"2010","journal-title":"J Clin Microbiol"},{"key":"key20190619124950825_ref1-bib12","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jmv.22085","article-title":"Sexual behavior and HPV infection in British women, by postal questionnaires and telephone interviews","volume":"83","author":"Almonte","year":"2011","journal-title":"J Med Virol"},{"key":"key20190619124950825_ref1-bib13","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1128\/JCM.01578-15","article-title":"The PapilloCheck assay for detection of high-grade cervical intraepithelial neoplasia","volume":"53","author":"Crosbie","year":"2015","journal-title":"J Clin Microbiol"},{"key":"key20190619124950825_ref1-bib14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1158\/1055-9965.EPI-14-0628","article-title":"The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials","volume":"24","author":"Veldhuijzen","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20190619124950825_ref1-bib15","volume-title":"HPV Primary Screening Pilots: Evaluation Report to the National Screening Committee","author":"Moss","year":"2015"},{"key":"key20190619124950825_ref1-bib16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20190619124950825_ref1-bib17","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ijc.28783","article-title":"Early detection of CIN3 and cervical cancer during long-term follow-up using HPV\/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme","volume":"135","author":"Luyten","year":"2014","journal-title":"Int J Cancer"},{"key":"key20190619124950825_ref1-bib18","doi-asserted-by":"publisher","first-page":"356.e1","DOI":"10.1016\/j.ajog.2007.07.049","article-title":"Risk assessment to guide the prevention of cervical cancer","volume":"197","author":"Castle","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"key20190619124950825_ref1-bib19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"key20190619124950825_ref1-bib20","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/ijc.26250","article-title":"International Collaboration of Epidemiological Studies of Cervical Cancer. Time since first sexual intercourse and the risk of cervical cancer","volume":"130","author":"Plummer","year":"2012","journal-title":"Int J Cancer"},{"key":"key20190619124950825_ref1-bib21","doi-asserted-by":"publisher","first-page":"i4924","DOI":"10.1136\/bmj.i4924","article-title":"Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands","volume":"355","author":"Dijkstra","year":"2016","journal-title":"BMJ"},{"key":"key20190619124950825_ref1-bib22","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/sj.bjc.6602049","article-title":"Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort","volume":"91","author":"Peto","year":"2004","journal-title":"Br J Cancer"},{"key":"key20190619124950825_ref1-bib23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ijc.30090","article-title":"The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples","volume":"139","author":"Ebisch","year":"2016","journal-title":"Int J Cancer"},{"key":"key20190619124950825_ref1-bib24","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":"The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice","volume":"97","author":"Khan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"key20190619124950825_ref1-bib25","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/S0140-6736(01)06809-X","article-title":"Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear","volume":"358","author":"Nobbenhuis","year":"2001","journal-title":"Lancet"},{"key":"key20190619124950825_ref1-bib26","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/1097-0142(196309)16:9<1160::AID-CNCR2820160910>3.0.CO;2-4","article-title":"Some histological aspects of behavior of epidermoid carcinoma in situ and related lesions of the uterine cervix. a long-term prospective study","volume":"16","author":"Koss","year":"1963","journal-title":"Cancer"},{"key":"key20190619124950825_ref1-bib27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0140-6736(98)12490-X","article-title":"Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study","volume":"354","author":"Nobbenhuis","year":"1999","journal-title":"Lancet"},{"key":"key20190619124950825_ref1-bib28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jcv.2015.11.015","article-title":"Triage of HPV positive women in cervical cancer screening","volume":"76","author":"Wentzensen","year":"2016","journal-title":"J Clin Virol"},{"key":"key20190619124950825_ref1-bib29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta23280\/hta23280.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2009252","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta23280\/hta23280.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2029448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:55:39Z","timestamp":1692114939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta23280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":29,"journal-issue":{"issue":"28","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["10.3310\/hta23280"],"URL":"https:\/\/doi.org\/10.3310\/hta23280","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}